Novo Nordisk's oral GLP‑1 weight‑loss pill gets EU approval amid strict European ad rules

The market for GLP‑1 drugs that treat obesity is expanding rapidly, with Novo Nordisk and Eli Lilly competing on injectable products such as Wegovy and Ozempic. In Europe, direct advertising of prescription medicines is largely prohibited, forcing companies to use product‑neutral campaigns. Novo Nordisk illustrated this with a walk‑through exhibition on the River Thames that discussed the challenges of losing weight without naming a specific drug.

In July, the European Commission granted its first approval for an oral GLP‑1 medication for obesity – a semaglutide tablet produced by Novo Nordisk. The once‑daily pill is prescription‑only, to be taken with water before breakfast, and is reported to deliver an average 17 % body‑weight reduction in clinical trials. It is positioned as an alternative for patients who cannot or do not wish to use injections and is said to have no major interactions with common drugs. The EU‑wide rollout will begin in member states, with national launch dates still pending.

The approval highlights the contrast between the United States, where prescription‑drug advertising is commonplace, and Europe’s tighter communication rules, underscoring the regulatory and marketing challenges facing weight‑loss pharmaceuticals.